Literature DB >> 9713958

Insight into Burkitt's lymphoma from immunoglobulin variable region gene analysis.

C J Chapman1, D Wright, F K Stevenson.   

Abstract

Analysis of usage of V(H) and V(L) genes, and the degree and pattern of somatic mutation, has been used to investigate the cell of origin and clonal history in cases of Burkitt's lymphoma (BL). Tumor cell lines and biopsy material from patients with endemic, sporadic and AIDS-associated BL have been compared. V(H) genes were most commonly derived from the V(H)3 (52%) and V(H)4 (39%) families. This shows a similar gene usage of the V(H)3 family to that seen in the normal peripheral blood repertoire (55%), but a biased usage of the V(H)4 family (22% in normal). There was no restriction in V(L) gene usage. This overall distribution was similar in all subsets of BL. In all categories, there was significant somatic mutation in both V(H) and V(L) sequences. There was no evidence for accumulation of mutations in cell lines cultured in vitro indicating that all mutations in BL-derived cell lines have accumulated in vivo. The mean percentage level of mutation +/- standard deviation was greater in endemic BL (V(H) = 7.7 +/- 4.0, V(L) = 5.3 +/- 2.2) and AIDS-associated BL (V(H) = 7.5 +/- 3.6, V(L) = 3.9 +/- 1.9) than in sporadic BL (V(H) = 4.0 +/- 2.5, V(L) = 2.2 +/- 1.2). The pattern of somatic hypermutation was similar in V(H) and V(L) sequences of the different types of BL although the light chain genes were less mutated. Mutational patterns in the V(H) genes did not reveal a conventional role for antigen in selection of tumor cell sequences in 23/25 V(H) genes analysed. In contrast, patterns in V(L) sequences were consistent with a role for antigen in 8/13 sBL +/- eBL cases and 8/17 cases overall. The presence of EBV did not seem to influence the quantity or pattern of somatic mutations. Evidence for intraclonal variation was seen in uncloned cell lines from cases of eBL and AIDS-associated BL and confirmed in biopsy material in some, but not all cases of eBL, sBL and AIDS-associated BL examined. These common features indicate that the B-cells involved in all types of BL are derived from cells that have traversed the germinal centre, and that the somatic mutation mechanism may still be operative following neoplastic transformation. Overall, in 10/30 cases, there was evidence of significant clustering of replacement amino acids, in CDRs, particularly in V(L), indicating that the B-cell of origin is likely to have been selected by antigen.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9713958     DOI: 10.3109/10428199809057539

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  15 in total

1.  Primary central nervous system lymphomas are derived from germinal-center B cells and show a preferential usage of the V4-34 gene segment.

Authors:  M Montesinos-Rongen; R Küppers; D Schlüter; T Spieker; D Van Roost; C Schaller; G Reifenberger; O D Wiestler; M Deckert-Schlüter
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

2.  High-throughput sequencing of the B-cell receptor in African Burkitt lymphoma reveals clues to pathogenesis.

Authors:  Katharine A Lombardo; David G Coffey; Alicia J Morales; Christopher S Carlson; Andrea M H Towlerton; Sarah E Gerdts; Francis K Nkrumah; Janet Neequaye; Robert J Biggar; Jackson Orem; Corey Casper; Sam M Mbulaiteye; Kishor G Bhatia; Edus H Warren
Journal:  Blood Adv       Date:  2017-03-21

Review 3.  HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma.

Authors:  Marta Epeldegui; Elena Vendrame; Otoniel Martínez-Maza
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

4.  Non-antigen-specific B-cell activation following murine gammaherpesvirus infection is CD4 independent in vitro but CD4 dependent in vivo.

Authors:  P G Stevenson; P C Doherty
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

5.  Immune surveillance and lymphoid malignancy in immunocompromised host.

Authors:  Patrick L Stevens; Nishitha M Reddy
Journal:  Am J Blood Res       Date:  2013-05-05

Review 6.  Epstein-Barr virus and Burkitt lymphoma.

Authors:  G Brady; G J MacArthur; P J Farrell
Journal:  J Clin Pathol       Date:  2007-12       Impact factor: 3.411

Review 7.  Immunoglobulin variable region structure and B-cell malignancies.

Authors:  H Kiyoi; T Naoe
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.319

8.  Deep sequencing of MYC DNA-binding sites in Burkitt lymphoma.

Authors:  Volkhard Seitz; Peter Butzhammer; Burkhard Hirsch; Jochen Hecht; Ines Gütgemann; Anke Ehlers; Dido Lenze; Elisabeth Oker; Anke Sommerfeld; Edda von der Wall; Christoph König; Christian Zinser; Rainer Spang; Michael Hummel
Journal:  PLoS One       Date:  2011-11-10       Impact factor: 3.240

9.  Burkitt lymphoma in the mouse.

Authors:  A L Kovalchuk; C F Qi; T A Torrey; L Taddesse-Heath; L Feigenbaum; S S Park; A Gerbitz; G Klobeck; K Hoertnagel; A Polack; G W Bornkamm; S Janz; H C Morse
Journal:  J Exp Med       Date:  2000-10-16       Impact factor: 14.307

10.  Screening for residual disease in pediatric burkitt lymphoma using consensus primer pools.

Authors:  Melissa Agsalda; Ian Kusao; David Troelstrup; Bruce Shiramizu
Journal:  Adv Hematol       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.